# HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

> **NCT04188951** · EARLY_PHASE1 · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]

## Key facts

- **NCT ID:** NCT04188951
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-04
- **Primary completion:** 2023-06-15
- **Final completion:** 2024-05-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188951, "HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04188951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*